Loss to follow-up common with IBD, but many have flare-ups

Loss to follow-up common with IBD, but many have flare-ups
(HealthDay)—Loss to follow-up is common with inflammatory bowel disease (IBD), and both low C-reactive protein levels and long travel time to the hospital are predictors of follow-up loss, according to a study published in the Journal of Gastroenterology and Hepatology.

Dae Hyung Woo, from the Yeungnam University College of Medicine in South Korea, and colleagues analyzed the frequency, predictors, and of patients with IBD who are lost to follow-up in outpatient clinics. Analysis included 285 newly diagnosed IBD patients (161 with and 124 with Crohn's disease) who were followed for at least 12 months.

The researchers found that 14.7 percent of the patients were lost to follow-up. Travel time to the clinic (odds ratio [OR], 2.37) and C-reactive protein levels at diagnosis (OR, 0.63) were significantly associated with follow-up loss. The vast majority (85.7 percent) of the 42 patients lost to follow-up revisited the clinic. Disease flare-up was the cause of revisit for 61.1 percent of patients. In 41.7 percent of patients, step-up treatment was needed. Steroids were introduced for 38.9 percent, while azathioprine and an antitumor necrosis factor agent were newly prescribed for 8.3 and 2.8 percent, respectively.

"Because most of follow-up loss patients experienced flare-up, clinicians need to try to encourage patients to keep their adherence," conclude the authors.


Explore further

Asthma tied to later inflammatory bowel disease

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Loss to follow-up common with IBD, but many have flare-ups (2018, October 25) retrieved 17 January 2019 from https://medicalxpress.com/news/2018-10-loss-follow-up-common-ibd-flare-ups.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more